ストックスクリーナーアプリを入手
9.97
1.68%
-0.17
Erasca Inc (ERAS) 最新ニュース
Erasca (ERAS) Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015 - Yahoo Finance
ERAS stock slumps nearly 40% after-hours: Fine print in 'positive' cancer trial reveals treatment-related death - MSN
5 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation - GlobeNewswire
Erasca Confronts Trial Fatality And Lawsuit As Valuation Debate Deepens - Sahm
Rambus posts downbeat Q1 earnings, joins Erasca, Spotify, Amkor Technology and other big stocks moving lower in Tuesday's pre-market session - MSN
Clear Street raises Erasca stock price target on combination trial deal - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Revolution Medicines Files Patent Infringement Lawsuit Against Erasca - HarianBasis.co
Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity - Insider Monkey
Erasca, Inc. Investigated for Securities Fraud Violations by Block & Leviton - marketscreener.com
ERAS Stock Price, Quote & Chart | ERASCA INC (NASDAQ:ERAS) - ChartMill
Erasca (ERAS) Recoups 16.9% Gain on Cancer Treatment Optimism - Insider Monkey
5 Stocks Delivering Eye-Popping Gains - Insider Monkey
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - MSN
Rambus Posts Downbeat Q1 Earnings, Joins Erasca, Spotify, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Sahm
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings - Sahm
The Nasdaq Biotechnology Index closed down more than 1.2%. Among its constituent stocks, Tango Therapeutics fell by 12.25%, Personalis dropped 8.36%, PTC Therapeutics decreased by 8.13%, Foghorn slid 8.12%, and Erasca declined 7.98%. - Bitget
ERAS stock slumps against RVMD rally — analyst stays bullish - MSN
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispu - GuruFocus
Why Erasca Stock Is Tumbling Despite Drug Hopes - TipRanks
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca stock sinks almost 50% after patient death in cancer drug trial - qz.com
Safety concerns arise after the death of a clinical trial participant: Erasca (ERAS.US), a cancer drug developer, sees its stock price halved with a single-day plunge of 48%. - 富途牛牛
Safety concerns arise following the death of a clinical trial participant: Shares of cancer drug developer Erasca (ERAS.US) plummet by 48% in a single day, experiencing a severe drop. - Moomoo
Erasca (ERAS) Valuation Check After Sharp Pullback And Premium Price To Book Ratio - simplywall.st
Erasca (ERAS) Shares Plunge 50% Following Trial Fatality and Patent Dispute - MEXC Exchange
5 Stocks Reeling From Huge Losses - Insider Monkey
Patient Death Drags Erasca (ERAS) Shares by 48% - Insider Monkey
Stock Crash: Cancer drug developer shares plunge 48% after patient dies - CNBC TV18
Boehringer’s obesity drug shows 16.6% weight loss; more data needed - statnews.com
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial - The Motley Fool
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death - Bloomberg.com
Erasca: Strong Data Overshadowed By A Patient Death And A Patent Fight (NASDAQ:ERAS) - Seeking Alpha
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
[ARS] Erasca, Inc. SEC Filing - Stock Titan
Erasca (NASDAQ: ERAS) details 2026 virtual meeting and executive pay - Stock Titan
These Stocks Are Today’s Movers: Oracle, AMD, Intel, Corning, Centene, Erasca, Rambus, Coca-Cola, UPS, and More - Barron's
Erasca (ERAS) Stock Crashes 50% After Patient Death in Cancer Drug Trial - MEXC
Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value - Investor's Business Daily
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015Slideshow (NASDAQ:ERAS) 2026-04-28 - Seeking Alpha
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data - marketscreener.com
Erasca (ERAS) Stock Plummets 50% Following Trial Death and Patent Dispute - parameter.io
Erasca shares cut in half after patient death in clinical trial By Investing.com - Investing.com Australia
Erasca shares cut in half after patient death in clinical trial - Investing.com
Erasca stock sinks 50% in race for pancreatic cancer miracle drug. What’s behind the sell-off? - MSN
Death a sticking point in Erasca molecular glue phase I - BioWorld News
BofA raises Erasca stock price target to $9 on trial data By Investing.com - Investing.com India
Revolution levels legal threat on Erasca as pancreatic cancer rivalry heats up - BioSpace
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results - BioPharma Dive
Erasca, Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Erasca, Inc. Investigated For Securities Fraud; Block & - GlobeNewswire
1.94%
1.54%
大文字化:
|
ボリューム (24 時間):